Etretinate Treatment of the Nevoid Basal Cell Carcinoma Syndrome

Therapeutic and Chemopreventive Effect

Authors

  • Emmilia Hodak M.D.,

    Corresponding author
    1. From the Department of Dermatology, Beilinson Medical Center, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Aleiandro Ginzburg M.D.,

    1. From the Department of Dermatology, Beilinson Medical Center, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Michael David M.D.,

    1. From the Department of Dermatology, Beilinson Medical Center, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author
  • Miriam Sandbank M.D.

    1. From the Department of Dermatology, Beilinson Medical Center, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Search for more papers by this author

Address for correspondence: Dr. E. Hodak, Department of Dermatology, Beilinson Medical Center, Petah Tiqva 41900, Israel.

Abstract

ABSTRACT: A patient suffering from the nevoid basal cell carcinoma syndrome, in whom various surgical and conservative treatment modalities had been tried previously, was placed on oral etretinate therapy. A therapeutic effect of the etretinate on existing basal cell carcinomas and a prophylactic effect in inhibiting new tumor formation were well demonstrated during the T3-montri period of treatment.

Ancillary